Publications by authors named "Hani Gabra"

100Publications

Emerging roles for the GPI-anchored tumor suppressor OPCML in cancers.

Cancer Gene Ther 2020 Jun 29. Epub 2020 Jun 29.

Department of Surgery and Cancer, Ovarian Cancer Action Research Centre, Imperial College London, London, W12 0NN, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41417-020-0187-6DOI Listing
June 2020

Proteomic analysis of malignant and benign endometrium according to obesity and insulin-resistance status using Reverse Phase Protein Array.

Transl Res 2020 04 27;218:57-72. Epub 2019 Dec 27.

Department of Surgery and Cancer, Institute of Reproductive and Developmental Biology, Faculty of Medicine, Imperial College London, London, UK; Queen Charlotte's and Chelsea - Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.trsl.2019.12.003DOI Listing
April 2020

Diffusion-weighted MRI in Advanced Epithelial Ovarian Cancer: Apparent Diffusion Coefficient as a Response Marker.

Radiology 2019 11 1;293(2):374-383. Epub 2019 Oct 1.

From the Cancer Research UK Cancer Imaging Centre, Division of Radiation Therapy and Imaging, The Institute of Cancer Research, London, England (J.M.W., J.C.W., E.P., D.J.C., N.M.d.S.); MRI Unit, Institute of Cancer Research and Royal Marsden Hospital, Royal Marsden NHS Foundation Trust, Downs Road, Sutton SM2 5PT, England (J.M.W., J.C.W., E.P., D.J.C., N.M.d.S.); Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, England (D.D., E.H.); Mount Vernon Cancer Centre, Mount Vernon Hospital, Northwood, England (M.H.); Department of Radiology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, England (S.F., A.N.P.); Cancer Research UK Cambridge Institute, Cambridge, England (J.D.B.); Addenbrooke's Hospital, Cambridge, England (J.D.B.); Department of Oncology, University of Cambridge, Cambridge, England (J.D.B.); Department of Gynaecological Oncology, Abertawe Bro Morgannwg Health Board, Morriston Hospital, Swansea, Wales (K.L.S.); Imaging Department, Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, England (R.A.Q.); Paul Strickland Scanner Centre, Mount Vernon Hospital, Northwood, England (N.J.T.); Imperial College London Hammersmith Campus, London, England (H.G.); Clinical Discovery Unit, Early Clinical Development, IMED Biotech Unit, Astrazeneca, Cambridge, England (H.G.); Department of Radiology, Abertawe Bro Morgannwg Health Board, Morriston Hospital, Swansea, Wales (L.M.); and Gynaecology Unit, Royal Marsden NHS Foundation Trust, Sutton, England (S.B.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1148/radiol.2019190545DOI Listing
November 2019

Anti-tumorigenic and Platinum-Sensitizing Effects of Apolipoprotein A1 and Apolipoprotein A1 Mimetic Peptides in Ovarian Cancer.

Front Pharmacol 2018 28;9:1524. Epub 2019 Jan 28.

Ovarian Cancer Action Research Centre, Imperial College London, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fphar.2018.01524DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360149PMC
January 2019

Risk factors for endometrial cancer: An umbrella review of the literature.

Int J Cancer 2019 10 20;145(7):1719-1730. Epub 2019 Feb 20.

Department of Surgery and Cancer, Institute of Reproductive and Developmental Biology, Faculty of Medicine, Imperial College London, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.31961DOI Listing
October 2019

Characterisation of tumour microvessel density during progression of high-grade serous ovarian cancer: clinico-pathological impact (an OCTIPS Consortium study).

Br J Cancer 2018 08 29;119(3):330-338. Epub 2018 Jun 29.

Department of Gynecology, European Competence Center for Ovarian Cancer, Campus Virchow Klinikum, Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-018-0157-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6070919PMC
August 2018

Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian Cancer.

Neoplasia 2018 03 22;20(3):280-288. Epub 2018 Feb 22.

Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Pathology, Charitéplatz 1, 10117 Berlin, Germany; Tumorbank Ovarian Cancer Network (TOC), Department of Gynecology, Charité University Hospital Berlin, Germany, Augustenburger Platz 1, 13353 Berlin, Germany. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neo.2018.01.007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5852388PMC
March 2018

The Tumor-Suppressor Protein OPCML Potentiates Anti-EGFR- and Anti-HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer.

Mol Cancer Ther 2017 10 3;16(10):2246-2256. Epub 2017 Aug 3.

Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-17-0081DOI Listing
October 2017

WWOX sensitises ovarian cancer cells to paclitaxel via modulation of the ER stress response.

Cell Death Dis 2017 07 27;8(7):e2955. Epub 2017 Jul 27.

Department of Surgery and Cancer, Molecular Therapeutics Unit and Ovarian Cancer Action Research Centre, Imperial College London, Hammersmith Hospital, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/cddis.2017.346DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5550887PMC
July 2017

British Gynaecological Cancer Society (BGCS) epithelial ovarian/fallopian tube/primary peritoneal cancer guidelines: recommendations for practice.

Eur J Obstet Gynecol Reprod Biol 2017 06 18;213:123-139. Epub 2017 Apr 18.

Pan Birmingham Gynaecological Cancer Centre, City Hospital Birmingham, School of Cancer Sciences, University of Birmingham, United Kingdom.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03012115173016
Publisher Site
http://dx.doi.org/10.1016/j.ejogrb.2017.04.016DOI Listing
June 2017

Surgery for Recurrent Uterine Cancer: Surgical Outcomes and Implications for Survival-A Case Series.

Int J Gynecol Cancer 2017 05;27(4):759-767

*Department of Gynecology-Obstetrics and Urology, Sapienza University of Rome, Rome, Italy; †West London Gynaecological Cancer Centre, Imperial College Healthcare NHS Trust; ‡Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, London, United Kingdom; §Division of Obstetrics and Gynecology, Department of Biomedical, Clinical and Experimental Sciences, University of Florence, Florence, Italy; ∥Mount Vernon Cancer Centre, London, United Kingdom; ¶Department of Anaesthetics, Hammersmith Hospital, Imperial College Healthcare NHS Trust; and #Department of Urology, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/IGC.0000000000000936DOI Listing
May 2017

Adiposity and cancer at major anatomical sites: umbrella review of the literature.

BMJ 2017 Feb 28;356:j477. Epub 2017 Feb 28.

Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5421437PMC
http://dx.doi.org/10.1136/bmj.j477DOI Listing
February 2017

Value of Neoadjuvant Chemotherapy for Newly Diagnosed Advanced Ovarian Cancer: A European Perspective.

J Clin Oncol 2017 02 9;35(6):587-590. Epub 2017 Jan 9.

Christina Fotopoulou, Imperial College London, London, United Kingdom; Jalid Sehouli, Charité Medical University of Berlin, Berlin, Germany; Giovanni Aletti, European Institute of Oncology, Milan, Italy; Philipp Harter, Kliniken Essen Mitte, Essen, Germany; Sven Mahner, Ludwig-Maximilians-University, Munich, Germany; Denis Querleu, Institut Bergonié, Bordeaux, France; Luis Chiva, Clínica Universidad de Navarra, Navarra, Spain; Hani Gabra, Imperial College London, London, United Kingdom; Nicoletta Colombo, European Institute of Oncology, Milan, Italy; and Andreas du Bois, Kliniken Essen Mitte, Essen, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.71.0723DOI Listing
February 2017

TRAP1 downregulation in human ovarian cancer enhances invasion and epithelial-mesenchymal transition.

Cell Death Dis 2016 12 15;7(12):e2522. Epub 2016 Dec 15.

Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università di Napoli 'Federico II', Napoli, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/cddis.2016.400DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5260997PMC
December 2016

Endocrine therapy in epithelial ovarian cancer.

Expert Rev Anticancer Ther 2017 Feb 24;17(2):109-117. Epub 2016 Dec 24.

b University of Edinburgh Cancer Research UK Centre, Institute of Genetics and Molecular Medicine, Western General Hospital , Edinburgh , UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737140.2017.1272414DOI Listing
February 2017

The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer.

Sci Signal 2016 10 4;9(448):ra97. Epub 2016 Oct 4.

Cancer Science Institute of Singapore, National University of Singapore, Singapore 117599, Singapore. Department of Obstetrics and Gynecology, National University Health System, Singapore 119228, Singapore. Department of Anatomy, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597, Singapore.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/scisignal.aaf8175DOI Listing
October 2016

Identification of proteomic and metabolic signatures associated with chemoresistance of human epithelial ovarian cancer.

Int J Oncol 2016 Oct 10;49(4):1651-65. Epub 2016 Aug 10.

Department of Gynecologic Oncology, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P.R. China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/ijo.2016.3652DOI Listing
October 2016

Integrative Analysis of Subcellular Quantitative Proteomics Studies Reveals Functional Cytoskeleton Membrane-Lipid Raft Interactions in Cancer.

J Proteome Res 2016 10 2;15(10):3451-3462. Epub 2016 Sep 2.

The University of Queensland Diamantina Institute, The University of Queensland , Translational Research Institute, Brisbane, Queensland 4102, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.jproteome.5b01035DOI Listing
October 2016

Maximal effort cytoreductive surgery for disseminated ovarian cancer in a UK setting: challenges and possibilities.

Arch Gynecol Obstet 2016 09 4;294(3):607-14. Epub 2016 Apr 4.

Centre for Perioperative Medicine and Critical Care Research, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, W12 0HS, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00404-016-4080-3DOI Listing
September 2016

Metabonomic analysis of ovarian tumour cyst fluid by proton nuclear magnetic resonance spectroscopy.

Oncotarget 2016 Feb;7(6):7216-26

Department of Histopathology, Hammersmith Hospital, Imperial College London, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.6891DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872780PMC
February 2016

Introduction to managing patients with recurrent ovarian cancer.

Authors:
Hani Gabra

EJC Suppl 2014 Dec 13;12(2):2-6. Epub 2015 Jan 13.

Ovarian Cancer Action Research Centre and Imperial College, London.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1359-6349(15)70003-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4683381PMC
December 2014

Foreword.

Authors:
Hani Gabra

EJC Suppl 2014 Dec 13;12(2). Epub 2015 Jan 13.

Ovarian Cancer Action Research Centre and Imperial College, London.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1359-6349(15)70002-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4683380PMC
December 2014

Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma.

Eur J Cancer 2015 Sep 31;51(14):1978-88. Epub 2015 Jul 31.

Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Center for RNA Interference and Non-Coding RNAs, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2015.07.012DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7304744PMC
September 2015

The next steps in improving the outcomes of advanced ovarian cancer.

Womens Health (Lond) 2015 Jun;11(3):355-67

Department of Medical Oncology, Hammersmith Hospital, Imperial College NHS, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/whe.15.6DOI Listing
June 2015

Whole-genome characterization of chemoresistant ovarian cancer.

Nature 2015 May;521(7553):489-94

1] Peter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia [2] Department of Pathology, University of Melbourne, Parkville, Victoria 3052, Australia [3] Sir Peter MacCallum Cancer Centre Department of Oncology, University of Melbourne, Parkville, Victoria 3052, Australia [4] Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, London W12 0HS, UK [5] Department of Biochemistry and Molecular Biology, University of Melbourne, Parkville, Victoria 3052, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nature14410DOI Listing
May 2015

Risk of Ovarian Cancer Relapse score: a prognostic algorithm to predict relapse following treatment for advanced ovarian cancer.

Int J Gynecol Cancer 2015 Mar;25(3):416-22

*Imperial College Healthcare NHS Trust, Garry Weston Cancer Centre, and †Ovarian Cancer Action Research Centre, Hammersmith Hospital; and ‡Division of Experimental Medicine, Imperial College London, Hammersmith Campus, London, United Kingdom.

View Article

Download full-text PDF

Source
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:land
Publisher Site
http://dx.doi.org/10.1097/IGC.0000000000000361DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4340599PMC
March 2015

The molecular genetics of hereditary and sporadic ovarian cancer: implications for the future.

Br Med Bull 2014 Dec;112(1):57-69

Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, Du Cane Road, London W12 0NN, UK

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/bmb/ldu034DOI Listing
December 2014

Molecular subtypes of serous borderline ovarian tumor show distinct expression patterns of benign tumor and malignant tumor-associated signatures.

Mod Pathol 2014 Mar 16;27(3):433-42. Epub 2013 Aug 16.

1] Department of Histopathology, Centre for Pathology, Imperial College London, Hammersmith Hospital, London, UK [2] Department of Pathology, Faculty of Medicine, University of Alexandria, Alexandria, Egypt.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/modpathol.2013.130DOI Listing
March 2014

Ovarian cancer: Ion channel and aquaporin expression as novel targets of clinical potential.

Eur J Cancer 2013 Jul 16;49(10):2331-44. Epub 2013 May 16.

Division of Cell and Molecular Biology, Neuroscience Solutions to Cancer Research Group, Imperial College London, South Kensington Campus, London SW7 2AZ, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2013.03.016DOI Listing
July 2013

Feasibility of trials in ovarian cancer by line of therapy and platinum sensitivity.

Int J Gynecol Cancer 2013 Mar;23(3):481-7

Ovarian Cancer Action Research Centre, Division of Oncology, Hammersmith Hospital Campus, Imperial College London, London, UK.

View Article

Download full-text PDF

Source
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:land
Publisher Site
http://dx.doi.org/10.1097/IGC.0b013e31828702f6DOI Listing
March 2013

A study to evaluate the cause of bone demineralization in gynecological cancer survivors.

Oncologist 2013 30;18(4):423-9. Epub 2013 Jan 30.

Division of Experimental Medicine and Toxicology, Department of Medicine, Imperial College, London, Hammersmith Hospital, London, Uk.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2012-0416DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3639529PMC
December 2013

Evolving concepts in the management of drug resistant ovarian cancer: dose dense chemotherapy and the reversal of clinical platinum resistance.

Cancer Treat Rev 2013 Apr 16;39(2):153-60. Epub 2012 May 16.

Division of Experimental Medicine, Imperial College London, Hammersmith Campus, Du Cane Road, W12 0HS London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2012.04.004DOI Listing
April 2013

Evaluation of 2-deoxy-2-[18F]fluoro-D-glucose- and 3'-deoxy-3'-[18F]fluorothymidine-positron emission tomography as biomarkers of therapy response in platinum-resistant ovarian cancer.

Mol Imaging Biol 2012 Dec;14(6):753-61

Comprehensive Cancer Imaging Centre, Department of Cancer & Surgery, Faculty of Medicine, Imperial College London, Hammersmith Hospital, 240 MRC Cyclotron Building, Du Cane Road, London, W12 0NN, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11307-012-0554-2DOI Listing
December 2012

Cerebral sinus thrombosis and leptomeningeal carcinomatosis in a patient with ovarian cancer.

J Clin Oncol 2012 Jan 12;30(2):e19-20. Epub 2011 Dec 12.

Department of Oncology, Hammersmith Hospital, Imperial College, Du Cane Rd, London W12 0NN, United Kingdom.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/30/2/e19.full.pdf
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2011.38.1426
Publisher Site
http://dx.doi.org/10.1200/JCO.2011.38.1426DOI Listing
January 2012

A study of symptoms described by ovarian cancer survivors.

Gynecol Oncol 2012 Apr 9;125(1):59-64. Epub 2011 Dec 9.

Department of Medicine, Imperial College, London, UK.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00908258110139
Publisher Site
http://dx.doi.org/10.1016/j.ygyno.2011.12.421DOI Listing
April 2012

DNA-PK mediates AKT activation and apoptosis inhibition in clinically acquired platinum resistance.

Neoplasia 2011 Nov;13(11):1069-80

Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, London, UK.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223610PMC
http://dx.doi.org/10.1593/neo.111032DOI Listing
November 2011

HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer.

Cancer Res 2011 Jul 13;71(13):4412-22. Epub 2011 May 13.

Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, Edinburgh, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-10-4111DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3130134PMC
July 2011

Genomic analysis reveals the molecular heterogeneity of ovarian clear cell carcinomas.

Clin Cancer Res 2011 Mar;17(6):1521-34

Department of Gynaecologic Oncology, Royal Marsden Hospital NHS Foundation Trust, The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, Royal Marsden Hospital, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-10-1688DOI Listing
March 2011

A new network for translational research in ovarian cancer. Interview by Helen Saul.

Authors:
Hani Gabra

Eur J Cancer 2010 Nov;46(16):2863

View Article

Download full-text PDF

Source
November 2010

Back to the future: Targeting molecular changes for platinum resistance reversal.

Authors:
Hani Gabra

Gynecol Oncol 2010 Sep;118(3):210-1

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2010.06.028DOI Listing
September 2010

The RNA binding protein Larp1 regulates cell division, apoptosis and cell migration.

Nucleic Acids Res 2010 Sep 29;38(16):5542-53. Epub 2010 Apr 29.

Department of Molecular Oncology, Imperial College, Hammersmith Campus, Du Cane Road, London W12 0HS, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/nar/gkq294DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2938220PMC
September 2010

First-line therapy for ovarian cancer with carboplatin followed by paclitaxel-gemcitabine (SCOTROC5): a feasibility study and comparative analysis of the SCOTROC series.

Eur J Cancer 2010 Jul 13;46(11):2020-6. Epub 2010 Apr 13.

Section of Medicine, The Institute of Cancer Research and Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2010.03.006DOI Listing
July 2010

WWOX tumour suppressor gene polymorphisms and ovarian cancer pathology and prognosis.

Eur J Cancer 2010 Mar 13;46(4):818-25. Epub 2010 Jan 13.

Ovarian cancer action (HHMT) Research Centre and Section of Molecular Therapeutics, Department of Oncology, Imperial College London Hammersmith Campus, Du Cane Road, London W12 0NN, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2009.12.021DOI Listing
March 2010

[Effect of WWOX gene on the attachment and adhesion of ovarian cancer cells].

Zhonghua Fu Chan Ke Za Zhi 2009 Jul;44(7):529-32

Department of Gynecologic Oncology, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China.

View Article

Download full-text PDF

Source
July 2009

[Effects of WWOX on ovarian cancer cell attachment in vitro].

Zhonghua Zhong Liu Za Zhi 2009 Jun;31(6):414-7

Department of Gynecologic Oncology, Affiliated Hospital of Guangxi Medical University, Nanning 530021, China.

View Article

Download full-text PDF

Source
June 2009

Dose density and altered scheduling of adjuvant chemotherapy in ovarian cancer: teaching old dogs new tricks?

Authors:
Hani Gabra

Discov Med 2009 Oct;8(42):140-4

Ovarian Cancer Action Research Centre, Imperial College London Hammersmith Campus, London, United Kingdom.

View Article

Download full-text PDF

Source
October 2009

Promising molecular targets in ovarian cancer.

Curr Opin Oncol 2009 Sep;21(5):412-9

Ovarian Cancer Action Research Centre, Imperial College London Hammersmith Campus, London, UK.

View Article

Download full-text PDF

Source
https://insights.ovid.com/crossref?an=00001622-200909000-000
Publisher Site
http://dx.doi.org/10.1097/CCO.0b013e32832eab1fDOI Listing
September 2009

WWOX gene expression abolishes ovarian cancer tumorigenicity in vivo and decreases attachment to fibronectin via integrin alpha3.

Cancer Res 2009 Jun 19;69(11):4835-42. Epub 2009 May 19.

University of Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-08-2974DOI Listing
June 2009

Future directions in the management of epithelial ovarian cancer.

Future Oncol 2008 Jun;4(3):403-11

Imperial College London, Ovarian Cancer Action Research Center, Hammersmith Campus, Du Cane Road, London, W12 0NN, UK.

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/14796694.4.3.403
Publisher Site
http://dx.doi.org/10.2217/14796694.4.3.403DOI Listing
June 2008

Endometrioid epithelial ovarian cancer : 20 years of prospectively collected data from a single center.

Cancer 2008 May;112(10):2211-20

Department of Medical Oncology, Edinburgh Cancer Center, Western General Hospital Campus, Edinburgh, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.23438DOI Listing
May 2008

Homozygous deletions may be markers of nearby heterozygous mutations: The complex deletion at FRA16D in the HCT116 colon cancer cell line removes exons of WWOX.

Genes Chromosomes Cancer 2008 May;47(5):437-47

Hutchison/MRC Research Centre and Department of Pathology, University of Cambridge, Cambridge, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/gcc.20548DOI Listing
May 2008

Evaluation of an inflammation-based prognostic score in patients with advanced ovarian cancer.

Eur J Cancer 2008 Jan 26;44(2):251-6. Epub 2007 Dec 26.

Department of Medicine, University of Sydney, Sydney, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2007.11.011DOI Listing
January 2008

p53 therapy in a patient with Li-Fraumeni syndrome.

Mol Cancer Ther 2007 May 4;6(5):1478-82. Epub 2007 May 4.

Mary Crowley Medical Research Center, Baylor University Medical Center, 60th Floor, 1717 Main Street, Dallas, TX 75201, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-07-0125DOI Listing
May 2007

Drug-induced exacerbation of glomus tumour pain.

J Hand Surg Br 2006 Dec 12;31(6):692. Epub 2006 Jun 12.

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.1016/J.JHSB.2006.04.018
Publisher Site
http://dx.doi.org/10.1016/j.jhsb.2006.04.018DOI Listing
December 2006

Ovarian carcinomas: CCN genes are aberrantly expressed and CCN1 promotes proliferation of these cells.

Clin Cancer Res 2005 Oct;11(20):7243-54

Division of Hematology/Oncology, Cedars-Sinai Medical Center, Los Angeles, California 90048, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-05-0231DOI Listing
October 2005

CpG island methylation of DNA damage response genes in advanced ovarian cancer.

Cancer Res 2005 Oct;65(19):8961-7

Centre for Oncology and Applied Pharmacology, Cancer Research UK Beatson Laboratories, University of Glasgow, Glasgow, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-05-1187DOI Listing
October 2005

Ovarian cancer.

Clin Evid 2003 Dec(10):2170-83

Cancer Research UK Edinburgh Oncology Unit Western General Hospital, Edinburgh, UK.

View Article

Download full-text PDF

Source
December 2003

Carcinosarcoma of the ovary: 19 years of prospective data from a single center.

Cancer 2004 May;100(10):2148-53

Cancer Research UK, University of Edinburgh Cancer Research Centre, Edinburgh, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.20256DOI Listing
May 2004